Profile data is unavailable for this security.
About the company
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
- Revenue in USD (TTM)11.10bn
- Net income in USD-988.90m
- Incorporated1989
- Employees6.10k
- LocationVertex Pharmaceuticals Inc50 Northern AvenueBOSTON 02210United StatesUSA
- Phone+1 (617) 341-6393
- Websitehttps://www.vrtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 14.09bn | 4.50bn | 61.30bn | 15.11k | 14.45 | 2.09 | 12.27 | 4.35 | 39.30 | 39.30 | 123.45 | 271.60 | 0.3917 | 0.6347 | 2.61 | 932,457.30 | 12.51 | 18.52 | 13.89 | 21.13 | 86.69 | 87.22 | 31.94 | 37.92 | 4.03 | -- | 0.0843 | -- | 8.27 | 12.55 | 11.61 | 15.84 | 15.46 | -- |
| Zoetis Inc | 9.29bn | 2.52bn | 68.99bn | 13.80k | 27.83 | 14.85 | 22.86 | 7.43 | 5.57 | 5.57 | 20.54 | 10.44 | 0.6529 | 1.07 | 7.00 | 672,898.60 | 17.77 | 15.25 | 21.83 | 18.31 | 70.98 | 70.18 | 27.22 | 26.32 | 1.04 | 21.14 | 0.5856 | 28.93 | 8.33 | 8.14 | 6.06 | 10.63 | 7.32 | 21.37 |
| Bristol-Myers Squibb Co | 47.64bn | 5.42bn | 95.36bn | 34.10k | 17.59 | 5.48 | 7.06 | 2.00 | 2.66 | 2.66 | 23.44 | 8.54 | 0.4976 | 4.27 | 5.12 | 1,396,950.00 | 5.68 | 0.6536 | 7.69 | 0.8175 | 74.69 | 76.63 | 11.41 | 1.52 | 1.17 | 7.39 | 0.7402 | 678.24 | 7.32 | 13.06 | -211.50 | -- | 8.34 | 7.91 |
| Vertex Pharmaceuticals Inc | 11.10bn | -988.90m | 120.40bn | 6.10k | -- | 7.30 | -- | 10.85 | -3.88 | -3.88 | 42.86 | 64.20 | 0.4744 | 1.43 | 6.17 | 1,819,623.00 | -4.23 | 14.06 | -5.04 | 16.67 | 86.03 | 87.35 | -8.91 | 26.28 | 2.29 | -- | 0.0067 | 0.00 | 11.66 | 21.50 | -114.80 | -- | 45.11 | -- |
| Gilead Sciences Inc | 28.74bn | 5.97bn | 136.38bn | 17.60k | 23.19 | 7.12 | 15.61 | 4.75 | 4.73 | 4.73 | 22.79 | 15.39 | 0.5098 | 3.45 | 6.35 | 1,632,671.00 | 10.58 | 5.26 | 13.63 | 6.38 | 78.29 | 78.47 | 20.76 | 12.54 | 1.23 | 7.80 | 0.5667 | 108.47 | 6.04 | 5.08 | -91.53 | -38.34 | -8.71 | 4.10 |
| Pfizer Inc | 62.46bn | 7.87bn | 145.83bn | 81.00k | 18.61 | 1.61 | 9.86 | 2.33 | 1.38 | 1.38 | 10.95 | 15.89 | 0.2911 | 1.46 | 5.47 | 771,148.10 | 3.68 | 7.45 | 4.49 | 9.43 | 74.57 | 69.10 | 12.64 | 20.37 | 0.9604 | 12.26 | 0.4066 | 64.22 | 6.84 | 9.10 | 275.82 | -5.27 | 2.32 | 3.13 |
| Amgen Inc | 34.13bn | 5.93bn | 158.77bn | 28.00k | 26.95 | 25.58 | 13.76 | 4.65 | 10.96 | 10.96 | 63.05 | 11.54 | 0.3743 | 1.59 | 4.58 | 1,218,786.00 | 6.51 | 8.43 | 8.50 | 10.66 | 64.07 | 72.81 | 17.39 | 21.90 | 0.878 | 7.06 | 0.9024 | 71.37 | 18.57 | 7.43 | -39.11 | -12.21 | 12.14 | 9.18 |
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Mar 2025 | 28.53m | 11.11% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 22.29m | 8.68% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 14.54m | 5.66% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 14.00m | 5.45% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 11.79m | 4.59% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2025 | 6.85m | 2.67% |
| Geode Capital Management LLCas of 31 Mar 2025 | 5.76m | 2.24% |
| Wellington Management Co. LLPas of 31 Mar 2025 | 5.26m | 2.05% |
| Jennison Associates LLCas of 31 Mar 2025 | 5.06m | 1.97% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2025 | 5.05m | 1.97% |
